Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:56-67.

An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine

Sara Nasser  1 , Ahmet A Kurdolgu, Tyler Izatt, Jessica Aldrich, Megan L Russell, Alexis Christoforides, Wiabhav Tembe, Jeffery A Keifer, Jason J Corneveaux, Sara A Byron, Karen M Forman, Clarice Zuccaro, Jonathan J Keats, Patricia M Lorusso, John D Carpten, Jeffrey M Trent, David W Craig
Affiliations
  • PMID: 25592568
Free article

An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine

Sara Nasser et al. Pac Symp Biocomput. 2015.
Free article

Abstract

The ability to rapidly sequence the tumor and germline DNA of an individual holds the eventual promise of revolutionizing our ability to match targeted therapies to tumors harboring the associated genetic biomarkers. Analyzing high throughput genomic data consisting of millions of base pairs and discovering alterations in clinically actionable genes in a structured and real time manner is at the crux of personalized testing. This requires a computational architecture that can monitor and track a system within a regulated environment as terabytes of data are reduced to a small number of therapeutically relevant variants, delivered as a diagnostic laboratory developed test. These high complexity assays require data structures that enable real-time and retrospective ad-hoc analysis, with a capability of updating to keep up with the rapidly changing genomic and therapeutic options, all under a regulated environment that is relevant under both CMS and FDA depending on application. We describe a flexible computational framework that uses a paired tumor/normal sample allowing for complete analysis and reporting in approximately 24 hours, providing identification of single nucleotide changes, small insertions and deletions, chromosomal rearrangements, gene fusions and gene expression with positive predictive values over 90%. In this paper we present the challenges in integrating clinical, genomic and annotation databases to provide interpreted draft reports which we utilize within ongoing clinical research protocols. We demonstrate the need to retire from existing performance measurements of accuracy and specificity and measure metrics that are meaningful to a genomic diagnostic environment. This paper presents a three-tier infrastructure that is currently being used to analyze an individual genome and provide available therapeutic options via a clinical report. Our framework utilizes a non-relational variant-centric database that is scaleable to a large amount of data and addresses the challenges and limitations of a relational database system. Our system is continuously monitored via multiple trackers each catering differently to the diversity of users involved in this process. These trackers designed in analytics web-app framework provide status updates for an individual sample accurate to a few minutes. In this paper, we also present our outcome delivery process that is designed and delivered adhering to the standards defined by various regulation agencies involved in clinical genomic testing.

PubMed Disclaimer

Similar articles

  • A decision support framework for genomically informed investigational cancer therapy.
    Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. Meric-Bernstam F, et al. J Natl Cancer Inst. 2015 Apr 11;107(7):djv098. doi: 10.1093/jnci/djv098. Print 2015 Jul. J Natl Cancer Inst. 2015. PMID: 25863335 Free PMC article. Review.
  • Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
    Carlson JA, Caldeira Xavier JC Jr, Tarasen A, Sheehan CE, Otto G, Miller VA, Stephens PJ, Elvin JA, Vergilio JA, Suh J, Gay LM, Ross JS. Carlson JA, et al. Am J Dermatopathol. 2017 Jan;39(1):1-13. doi: 10.1097/DAD.0000000000000729. Am J Dermatopathol. 2017. PMID: 28045747
  • Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H, Eng K, Mosquera JM, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J, Park K, Banfelder J, Prandi D, Madhukar N, Zhang T, Padilla J, Greco N, McNary TJ, Herrscher E, Wilkes D, MacDonald TY, Xue H, Vacic V, Emde AK, Oschwald D, Tan AY, Chen Z, Collins C, Gleave ME, Wang Y, Chakravarty D, Schiffman M, Kim R, Campagne F, Robinson BD, Nanus DM, Tagawa ST, Xiang JZ, Smogorzewska A, Demichelis F, Rickman DS, Sboner A, Elemento O, Rubin MA. Beltran H, et al. JAMA Oncol. 2015 Jul;1(4):466-74. doi: 10.1001/jamaoncol.2015.1313. JAMA Oncol. 2015. PMID: 26181256 Free PMC article.
  • Genomic medicine and risk prediction across the disease spectrum.
    Kotze MJ, Lückhoff HK, Peeters AV, Baatjes K, Schoeman M, van der Merwe L, Grant KA, Fisher LR, van der Merwe N, Pretorius J, van Velden DP, Myburgh EJ, Pienaar FM, van Rensburg SJ, Yako YY, September AV, Moremi KE, Cronje FJ, Tiffin N, Bouwens CS, Bezuidenhout J, Apffelstaedt JP, Hough FS, Erasmus RT, Schneider JW. Kotze MJ, et al. Crit Rev Clin Lab Sci. 2015;52(3):120-37. doi: 10.3109/10408363.2014.997930. Epub 2015 Jan 19. Crit Rev Clin Lab Sci. 2015. PMID: 25597499 Review.
  • Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C, Londin E, Fortina P. Paolillo C, et al. Scand J Clin Lab Invest Suppl. 2016;245:S84-91. doi: 10.1080/00365513.2016.1210331. Epub 2016 Aug 17. Scand J Clin Lab Invest Suppl. 2016. PMID: 27542004
See all similar articles

Cited by

See all "Cited by" articles

Publication types

Substances